C
Description
Swedish clinical-stage pharma company founded by pioneers in GERD treatment from Astra/AstraZeneca. Develops linaprazan glurate (PCAB), a new-class acid blocker for erosive GERD. Phase III (HEEALING 1) initiated in September 2025.